ArticleCancer medicine2026
Chemo-Immunotherapy, a Combination Approach for the Treatment of HER2-Positive Breast Cancer in a Mouse Model.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The discovery of tumor-associated antigens has been a significant milestone for cancer therapy as the current conventional therapies (radiotherapy, chemotherapy) were found to be insufficient in terms of cancer treatment. Human epidermal growth factor receptor (HER2) is a tumor-associated antigen, aberrantly found in various cancers, including breast cancer. Today, most treatment strategies are skewed toward combination therapies rather than monotherapies, as they have been found primarily ineffective due to patients' resistance mechanisms. A combination of multiple therapeutic approaches (passive/active immunotherapy, conventional therapies) was found to be more effective in the clinic. This study investigated various vaccine combinations against the 4 T1-HER2 xenograft model of Balb/c mice. Eight different groups of vaccine formulations were tested to find the best synergistic combination, including combinations of BM-DC-based vaccine, peptide-based vaccine, anti-PD-L1, Doxorubicin, and QS-21 adjuvant. Triple combination groups of immunotherapies exerted better activities in terms of tumor dimensions as Doxorubicin+BM-DC-HER2/Neu + QS-21 + anti-PD-L1 and Doxorubicin+HER2/Neu + QS-21 + anti-PD-L1 groups significantly decreased tumor dimensions. Similar groups also demonstrated a better stimulation of lymphocytes and IFN-γ cytokine in the flow cytometry study, inducing a HER2/Neu-specific antibody response in ELISA studies. Doxorubicin+BM-DC-HER2/Neu + QS-21 + anti-PD-L1 combination demonstrated significantly higher specific cytotoxicity in lactate dehydrogenase data, as well as the CD4+ and CD8+ responses in the immunohistochemical study. In conclusion, these data indicated that the Doxorubicin+BM-DC + HER2/Neu + QS-21 + anti-PD-L1 vaccine combination synergistically generated a promising activity in terms of tumor dimension and immune response stimulation against the HER2 overexpressing breast cancer model in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.